{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:56:39Z","timestamp":1785455799378,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018201","name":"Syndax Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018201","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40261-025-01438-7","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T11:52:59Z","timestamp":1747482779000},"page":"327-334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study"],"prefix":"10.1007","volume":"45","author":[{"given":"Miwa","family":"Haranaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Kinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-3905","authenticated-orcid":false,"given":"Kazumi","family":"Suzukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"issue":"2","key":"1438_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","volume":"21","author":"S Arai","year":"2015","unstructured":"Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266\u201374.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1438_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","volume":"129","author":"SJ Lee","year":"2017","unstructured":"Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30\u20137.","journal-title":"Blood"},{"issue":"6","key":"1438_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.12.027","volume":"27","author":"CR Bachier","year":"2021","unstructured":"Bachier CR, Aggarwal SK, Hennegan K, et al. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US Claims analysis. Transplant Cell Ther. 2021;27(6): e504.","journal-title":"Transplant Cell Ther."},{"issue":"5","key":"1438_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/17474086.2019.1605288","volume":"12","author":"M Csanadi","year":"2019","unstructured":"Csanadi M, Agh T, Tordai A, et al. A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. Expert Rev Hematol. 2019;12(5):311\u201323.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"1438_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbmt.2015.10.018","volume":"22","author":"M Arora","year":"2016","unstructured":"Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(3):449\u201355.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"1438_CR6","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.bbmt.2008.09.017","volume":"14","author":"ME Flowers","year":"2008","unstructured":"Flowers ME, Storer B, Carpenter P, et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(12):1380\u20134.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1438_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","volume":"24","author":"SJ Lee","year":"2018","unstructured":"Lee SJ, Nguyen TD, Onstad L, et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24(3):555\u201362.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1438_CR8","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1172\/JCI75935","volume":"124","author":"KA Alexander","year":"2014","unstructured":"Alexander KA, Flynn R, Lineburg KE, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Investig. 2014;124(10):4266\u201380.","journal-title":"J Clin Investig"},{"issue":"10","key":"1438_CR9","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.22.00958","volume":"41","author":"CL Kitko","year":"2023","unstructured":"Kitko CL, Arora M, DeFilipp Z, et al. Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study. J Clin Oncol. 2023;41(10):1864\u201375.","journal-title":"J Clin Oncol"},{"key":"1438_CR10","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3389\/fimmu.2019.02019","volume":"10","author":"W Lin","year":"2019","unstructured":"Lin W, Xu D, Austin CD, et al. Function of CSF1 and IL34 in macrophage homeostasis, inflammation, and cancer. Front Immunol. 2019;10:2019.","journal-title":"Front Immunol"},{"issue":"11","key":"1438_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","volume":"391","author":"D Wolff","year":"2024","unstructured":"Wolff D, Cutler C, Lee SJ, et al. Axatilimab in recurrent or refractory chronic graft-versus-host disease. N Engl J Med. 2024;391(11):1002\u201314.","journal-title":"N Engl J Med"},{"key":"1438_CR12","unstructured":"Tiessen R, Visser A, Tadema H, et al. First in human, single ascending dose study in healthy volunteers of SNDX-6352, a humanized IgG4 monoclonal antibody targeting colony stimulating factor-1 receptor (CSF-1R). J Immunother Cancer. 2017;5(suppl_2):244."},{"issue":"19","key":"1438_CR13","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1182\/blood-2010-02-266296","volume":"116","author":"KP MacDonald","year":"2010","unstructured":"MacDonald KP, Palmer JS, Cronau S, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood. 2010;116(19):3955\u201363.","journal-title":"Blood"},{"key":"1438_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev-immunol-042617-053119","volume":"37","author":"PB Narasimhan","year":"2019","unstructured":"Narasimhan PB, Marcovecchio P, Hamers AAJ, et al. Nonclassical monocytes in health and disease. Annu Rev Immunol. 2019;37:439\u201356.","journal-title":"Annu Rev Immunol"},{"issue":"23","key":"1438_CR15","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1182\/blood.V126.23.3127.3127","volume":"123","author":"K Reinhardt","year":"2015","unstructured":"Reinhardt K, Handgretinger R, Bethge W, Holzer U. Role of monocytes and pro-inflammatory Th17 cells expressing multi-drug resistance protein type 1 in the pathogenesis of graft-versus-host disease. Blood. 2015;123(23):3127.","journal-title":"Blood"},{"issue":"12","key":"1438_CR16","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/s41409-018-0187-4","volume":"53","author":"T Konuma","year":"2018","unstructured":"Konuma T, Kohara C, Watanabe E, et al. Circulating monocyte subsets in human chronic graft-versus-host disease. Bone Marrow Transplant. 2018;53(12):1532\u201340.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"1438_CR17","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1182\/blood-2005-01-0062","volume":"106","author":"T Banovic","year":"2005","unstructured":"Banovic T, MacDonald KP, Morris ES, et al. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood. 2005;106(6):2206\u201314.","journal-title":"Blood"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01438-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:02:57Z","timestamp":1749200577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01438-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01438-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"2 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Incyte Biosciences Japan GK (Tokyo, Japan). The open access fee was funded by Incyte Corporation (Wilmington, DE, USA) and Syndax Pharmaceuticals (New York, NY, USA). Employees of Incyte Biosciences Japan GK and Incyte Corporation participated in study design, data collection, analysis, interpretation, and manuscript writing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M.H. is an employee of SOSEIKAI Hakata Clinic. K.K. and K.S. are employees of Incyte Biosciences Japan GK and shareholders of Incyte Corporation. Y.Y., H.L., and M.P. are employees and shareholders of Incyte Corporation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase 1 studies) for which the product and indication have been approved on or after 1 January 2020 in \u2265 1 major market (e.g., USA, EU, JPN). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte\u2019s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at: .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study was conducted in accordance with the provisions of the 1964 Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice, and other applicable local regulations. Study protocols were approved by the SOUSEIKAI Hakata Clinic Institutional Review Board (approval no. VV-TMF-228501) on 9 February 2023.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent\/assent was provided by all participants prior to enrollment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to study conception and design, data collection, data analysis, manuscript preparation, and commented on previous versions of the manuscript. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}